AIRLINK 166.94 Decreased By ▼ -1.57 (-0.93%)
BOP 9.71 Decreased By ▼ -0.08 (-0.82%)
CNERGY 7.82 Decreased By ▼ -0.17 (-2.13%)
CPHL 88.87 Increased By ▲ 0.90 (1.02%)
FCCL 44.58 Increased By ▲ 0.65 (1.48%)
FFL 15.41 Decreased By ▼ -0.11 (-0.71%)
FLYNG 28.62 Increased By ▲ 0.68 (2.43%)
HUBC 139.39 Increased By ▲ 1.42 (1.03%)
HUMNL 12.07 Decreased By ▼ -0.30 (-2.43%)
KEL 4.20 Decreased By ▼ -0.04 (-0.94%)
KOSM 5.48 Decreased By ▼ -0.08 (-1.44%)
MLCF 67.46 Increased By ▲ 2.67 (4.12%)
OGDC 212.37 Increased By ▲ 0.68 (0.32%)
PACE 5.53 Decreased By ▼ -0.20 (-3.49%)
PAEL 44.31 Decreased By ▼ -0.71 (-1.58%)
PIAHCLA 16.80 Decreased By ▼ -0.29 (-1.7%)
PIBTL 9.37 Increased By ▲ 0.14 (1.52%)
POWER 14.28 Decreased By ▼ -0.17 (-1.18%)
PPL 164.05 Decreased By ▼ -2.35 (-1.41%)
PRL 29.41 Decreased By ▼ -1.24 (-4.05%)
PTC 21.30 Increased By ▲ 0.10 (0.47%)
SEARL 88.99 Decreased By ▼ -1.48 (-1.64%)
SSGC 40.49 Decreased By ▼ -0.56 (-1.36%)
SYM 14.64 Increased By ▲ 0.16 (1.1%)
TELE 7.17 Decreased By ▼ -0.22 (-2.98%)
TPLP 9.15 Decreased By ▼ -0.22 (-2.35%)
TRG 64.27 Decreased By ▼ -0.73 (-1.12%)
WAVESAPP 9.42 Decreased By ▼ -0.09 (-0.95%)
WTL 1.29 Decreased By ▼ -0.02 (-1.53%)
YOUW 3.65 Decreased By ▼ -0.07 (-1.88%)
BR100 12,327 Increased By 71.3 (0.58%)
BR30 36,803 Increased By 80.1 (0.22%)
KSE100 115,469 Increased By 449.5 (0.39%)
KSE30 35,563 Increased By 234.3 (0.66%)
Business & Finance

European Commission signs third contract with BioNTech-Pfizer for 1.8bn vaccine doses

  • The contract reserves the doses on behalf of all European Union member states, between end 2021 to 2023, the statement added. The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU.
Published May 20, 2021

The European Commission said on Thursday that it signed a third contract with pharmaceutical companies BioNTech SE and Pfizer Inc for an additional 1.8 billion doses of the coronavirus vaccine.

The contract reserves the doses on behalf of all European Union member states, between end 2021 to 2023, the statement added. The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU.

Comments

Comments are closed.